Rivipansel subcutaneous

Drug Profile

Rivipansel subcutaneous

Alternative Names: PF-06460031/PF-06744547; PF-06460031/rHuPH20; Rivipansel/PF-06744547; Rivipansel/rHuPH20

Latest Information Update: 10 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlycoMimetics
  • Developer Pfizer
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors; PCSK9 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sickle cell anaemia

Most Recent Events

  • 07 Nov 2016 Discontinued - Phase-I for Sickle cell anaemia (In volunteers) in Belgium (SC)
  • 01 Apr 2016 Pfizer completes a phase I trial in Healthy volunteers in Belgium (SC) (NCT02217917)
  • 01 Oct 2015 Phase-I clinical trials in Sickle cell anaemia (In volunteers) in Belgium (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top